Are you ready to embrace the future of trading? Tickeron's AI robots empower investors to make smarter decisions.
Incyte Corp (INCY, $62.58) finds itself in the midst of a bearish trend, as indicated by A.I.dvisor's prediction of a potential Downtrend continuation. Shareholders have endured a challenging period, with a notable 38% decline in share price over the past three years and an additional 19% drop in the last quarter. To gain a comprehensive understanding of the company's current situation, it is essential to examine the correlation between shareholder returns and Incyte's underlying economics.
Over the past three years, while the broader market has returned approximately 40%, shareholders of Incyte have faced a contrasting experience with a significant decline of 38%. This divergence raises questions about the company's economic performance and its ability to generate returns for its shareholders.
Delving deeper into Incyte's economic performance, it becomes crucial to analyze whether the company's financials align with the disappointing shareholder returns. By scrutinizing key indicators, such as revenue growth, profitability, and efficiency, we can shed light on the underlying factors contributing to the company's stock performance.
Incyte Corp's economic performance has a critical role to play in determining its future prospects. By assessing the correlation between shareholder returns and the company's financial metrics, we can better understand whether there are any disparities or potential catalysts that may drive a turnaround. This analysis provides valuable insights for investors seeking to navigate the evolving landscape of Incyte Corp and make informed decisions regarding their investment strategy.
It is essential to approach Incyte Corp's current bearish trend with a comprehensive understanding of its underlying economics and the factors influencing its share price. By staying informed and aware of the correlation between shareholder returns and the company's financial performance, investors can make more informed decisions about their investment in Incyte and evaluate its future potential.
The 10-day moving average for INCY crossed bearishly below the 50-day moving average on September 14, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on September 12, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on INCY as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
INCY moved below its 50-day moving average on September 13, 2023 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for INCY entered a downward trend on September 29, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for INCY's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .
INCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INCYβs price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.770) is normal, around the industry mean (22.693). P/E Ratio (35.971) is within average values for comparable stocks, (131.605). Projected Growth (PEG Ratio) (0.438) is also within normal values, averaging (4.099). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (3.755) is also within normal values, averaging (304.777).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INCYβs unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of drugs
Industry Biotechnology
A.I.dvisor indicates that over the last year, INCY has been loosely correlated with EXEL. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then EXEL could also see price increases.
Ticker / NAME | Correlation To INCY | 1D Price Change % | ||
---|---|---|---|---|
INCY | 100% | -1.42% | ||
EXEL - INCY | 45% Loosely correlated | -2.50% | ||
IMGN - INCY | 41% Loosely correlated | -0.84% | ||
GMAB - INCY | 40% Loosely correlated | -0.20% | ||
AXON - INCY | 39% Loosely correlated | +1.48% | ||
REGN - INCY | 38% Loosely correlated | -1.35% | ||
More |